Epigenomics AG operates in the Commercial physical research sector. Epigenomics AG is a Germany-based company engaged in the molecular diagnostics sector. It divides its products into two segments: solutions for early diagnosis of cancer and products for special diagnosis of cancer. Epigenomics AG produces, develops and sells blood tests that help in the diagnosis of the colorectal, prostate and lung cancer. The Company also offers services in the field of identification and development of methylated deoxyribonucleic acid (DNA) biomarkers. Industry partners and the medical and life science communities can access the Company's portfolio of filed patent families covering DNA methylation technologies and biomarkers, as well as its DNA methylation expertise through research products, biomarker services, in vitro diagnostics (IVD) development collaborations and licensing. It develops its solutions together with its commercial partners, Abbott Molecular Inc and Quest Diagnostics Inc. The Company has a subsidiary in the United States, Epigenomics, Inc. In our complete report available for purchase the company is compared to: November AG, Adinotec AG and Wilex Ag.